MGL-3196

CAS NO.：920509-32-6
Empirical Formula: C17H12Cl2N6O4
Molecular Weight: 435.22
MDL number: MFCD26142653
SAFETY DATA SHEET (SDS)
Update Date: 2024-11-19 20:33:22

What is MGL-3196?

Description

MGL-3196 is an agonist of thyroid hormone receptor β (TRβ; EC₅₀s = 0.21 and 3.74 μM for TRβ and TRα, respectively). It also inhibits ether-a-go-go-related gene (ERG) potassium channels (IC₅₀ = 30 μM). MGL-3196 is a liver-directed compound, with a liver to plasma ratio of 8:1 in mice with diet-induced obesity (DIO), which reduces the likelihood of adverse effects from systemic exposure. It does not affect the expression of α-myosin heavy chain (α-MHC) in a rat model of hypothyroidism, an effect mediated by TRα, indicating low potential for cardiac adverse effects. MGL-3196 lowers non-HDL cholesterol and liver triglycerides without affecting thyroid stimulating hormone (Tsh) levels in rat and rabbit models of hypercholesterolemia. It also lowers plasma glucose levels and improves insulin sensitivity in DIO mice. Formulations containing MGL-3196 are in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) and familial hypercholesterolemia.

Properties of MGL-3196

Density	1.65±0.1 g/cm3(Predicted)
storage temp.	Inert atmosphere,Store in freezer, under -20°C
solubility	DMSO:59.0(Max Conc. mg/mL);135.56(Max Conc. mM)
form	A crystalline solid
pka	3.96±0.40(Predicted)
color	Yellow to orange

Safety information for MGL-3196

Signal word	Warning
Pictogram(s)	Exclamation Mark Irritant GHS07
GHS Hazard Statements	H302:Acute toxicity,oral H315:Skin corrosion/irritation H319:Serious eye damage/eye irritation H335:Specific target organ toxicity, single exposure;Respiratory tract irritation
Precautionary Statement Codes	P261:Avoid breathing dust/fume/gas/mist/vapours/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.